Literature DB >> 23305591

MicroRNA expression signatures in intraductal papillary mucinous neoplasm of the pancreas.

Nir Lubezky1, Shelly Loewenstein, Menahem Ben-Haim, Eli Brazowski, Sylvia Marmor, Metsada Pasmanik-Chor, Varda Oron-Karni, Gideon Rechavi, Joseph M Klausner, Guy Lahat.   

Abstract

BACKGROUND: Intraductal papillary mucinous neoplasms (IPMN) represent a spectrum of tumors that range from low-grade (LG) dysplastic tumors to invasive cancer. Identification of IPMN at high risk for malignant transformation is important for the prevention and early treatment of pancreatic cancer. The roles of microRNA expression in the development of IPMN have not been extensively evaluated.
METHODS: Expression patterns of 846 human microRNAs (miRNAs) was analyzed using microRNA microarray in 55 tissues, including LG IPMN (n = 10), moderate-grade (MG) IPMN (n = 5), high-grade (HG) IPMN (n = 5), invasive cancer with IPMN (IPMC; n = 10), pancreatic ductal adenocarcinoma without IPMN (PDA; n = 5), LG IPMN extracted from specimens that contain IPMC (LG_Ca; n = 10), and normal pancreatic tissues (n = 10).
RESULTS: Fourteen miRNAs were differentially expressed in all IPMN tissues compared with normal pancreatic tissue. Expression level of 3 miRNAs was proportional to dysplasia level. Hierarchical clustering demonstrated grouping of 2 IPMN subgroups: LG and MG IPMN verses HG IPMN and IPMC. Expression of 15 miRNAs was significantly different between these groups. LG_Ca tissues clustered with the HG IPMC group, and 12 miRNAs were differentially expressed in LG_Ca, HG lesions, and IPMC compared with LG lesions. The expression patterns of selected miRNAs were validated using quantitative reverse-transcription real-time polymerase chain reaction. Hierarchical clustering demonstrated microRNA expression profile in IPMC was significantly different from PDA, suggesting that different pathways are involved in these cancer types.
CONCLUSION: This study demonstrates that miRNAs are involved in the development and progression of IPMN. We identified potential targets for diagnosis, prognostication, and treatment of IPMN.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23305591     DOI: 10.1016/j.surg.2012.11.016

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  26 in total

1.  Plasma MicroRNAs as Novel Biomarkers for Patients with Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Jennifer Permuth-Wey; Dung-Tsa Chen; William J Fulp; Sean J Yoder; Yonghong Zhang; Christina Georgeades; Kazim Husain; Barbara Ann Centeno; Anthony M Magliocco; Domenico Coppola; Mokenge Malafa
Journal:  Cancer Prev Res (Phila)       Date:  2015-09

Review 2.  Novel Biomarkers for Pancreatic Cysts.

Authors:  Harkirat Singh; Kevin McGrath; Aatur D Singhi
Journal:  Dig Dis Sci       Date:  2017-02-14       Impact factor: 3.199

3.  Multi-institutional Validation Study of Pancreatic Cyst Fluid Protein Analysis for Prediction of High-risk Intraductal Papillary Mucinous Neoplasms of the Pancreas.

Authors:  Mohammad A Al Efishat; Marc A Attiyeh; Anne A Eaton; Mithat Gönen; Denise Prosser; Anna E Lokshin; Carlos Fernández-Del Castillo; Keith D Lillemoe; Cristina R Ferrone; Ilaria Pergolini; Mari Mino-Kenudson; Neda Rezaee; Marco Dal Molin; Matthew J Weiss; John L Cameron; Ralph H Hruban; Michael I D'Angelica; T Peter Kingham; Ronald P DeMatteo; William R Jarnagin; Christopher L Wolfgang; Peter J Allen
Journal:  Ann Surg       Date:  2018-08       Impact factor: 12.969

4.  Tumor-associated Neutrophils and Malignant Progression in Intraductal Papillary Mucinous Neoplasms: An Opportunity for Identification of High-risk Disease.

Authors:  Eran Sadot; Olca Basturk; David S Klimstra; Mithat Gönen; Anna Lokshin; Richard Kinh Gian Do; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; William R Jarnagin; Peter J Allen
Journal:  Ann Surg       Date:  2015-12       Impact factor: 12.969

Review 5.  Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Marina Paini; Stefano Crippa; Stefano Partelli; Filippo Scopelliti; Domenico Tamburrino; Andrea Baldoni; Massimo Falconi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  Cyst fluid biomarkers for intraductal papillary mucinous neoplasms of the pancreas: a critical review from the international expert meeting on pancreatic branch-duct-intraductal papillary mucinous neoplasms.

Authors:  Ajay V Maker; Silvia Carrara; Nigel B Jamieson; Mario Pelaez-Luna; Anne Marie Lennon; Marco Dal Molin; Aldo Scarpa; Luca Frulloni; William R Brugge
Journal:  J Am Coll Surg       Date:  2014-11-06       Impact factor: 6.113

Review 7.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

8.  A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma.

Authors:  Amy L Collins; Sylwia Wojcik; James Liu; Wendy L Frankel; Hansjuerg Alder; Lianbo Yu; Thomas D Schmittgen; Carlo M Croce; Mark Bloomston
Journal:  Ann Surg Oncol       Date:  2013-09-18       Impact factor: 5.344

9.  Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer.

Authors:  Ganepola Ap Ganepola; John R Rutledge; Paritosh Suman; Anusak Yiengpruksawan; David H Chang
Journal:  World J Gastrointest Oncol       Date:  2014-01-15

Review 10.  MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer.

Authors:  Marion Gayral; Sébastien Jo; Naima Hanoun; Alix Vignolle-Vidoni; Hubert Lulka; Yannick Delpu; Aline Meulle; Marlène Dufresne; Marine Humeau; Maël Chalret du Rieu; Barbara Bournet; Janick Sèlves; Rosine Guimbaud; Nicolas Carrère; Louis Buscail; Jérôme Torrisani; Pierre Cordelier
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.